Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP2K7 | O14733 | 13/20 | 0.45 |
| ▸ | KDR | P35968 | 5/20 | 0.43 |
| ▸ | TNNI3K | Q59H18 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5449168 | 0.88 | MAP2K7 (0.42) | MAP2K7KDRTNNI3K | |
| SCHEMBL5345519 | 0.82 | MAP2K7 (0.47) | MAP2K7KDRTNNI3KSMN1; SMN2 | |
| SCHEMBL5337632 | 0.82 | KDR (0.61) | KDR | |
| SCHEMBL5349411 | 0.79 | GRM5 (0.41) | KDRSMN1; SMN2MEN1ALDH1A1LMNA | |
| SCHEMBL5416867 | 0.78 | MAP2K7 (0.50) | MAP2K7KDRTNNI3KTSHRSMN1; SMN2 | |
| SCHEMBL5336073 | 0.78 | MAP2K7 (0.45) | MAP2K7KDRTNNI3KSMN1; SMN2 | |
| SCHEMBL5372666 | 0.76 | MAP2K7 (0.47) | MAP2K7KDRTNNI3KSMN1; SMN2MEN1 | |
| SCHEMBL5450708 | 0.75 | MAP2K7 (0.56) | MAP2K7KDRALDH1A1 | |
| SCHEMBL5422702 | 0.75 | MAP2K7 (0.44) | MAP2K7KDRTNNI3KSMN1; SMN2 | |
| SCHEMBL5340417 | 0.75 | MAP2K7 (0.46) | MAP2K7KDRTNNI3KSMN1; SMN2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070155764-A1 | NOVEL SUBSTITUTED PYRIMIDINYLOXY UREAS USEFUL AS INHIBITORS OF PROTEIN KINASES | KALYPSYS, INC. (US) | 2007-07-05 | — | — | US | disclosed |
| WO-2007076473-A2 | SUBSTITUTED PYRIMIDINYLOXY UREAS USEFUL AS INHIBITORS OF PROTEIN KINASES | KALYPSYS, INC. (US) | 2007-07-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070155764-A1 | NOVEL SUBSTITUTED PYRIMIDINYLOXY UREAS USEFUL AS INHIBITORS OF PROTEIN KINASES | BRAF, ARAF, RAF1 | MAP2K7 141/4885KDR 555/4885TNNI3K 112/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.